TheraRadar
← Back
Data updated: Jun 28, 2026

LEDERLE

Big Pharma

LEDERLE is a major pharmaceutical company focused on Infectious Disease, Respiratory, Cardiovascular.

1941
Since
49
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

LEDERLE's Key Drugs

LEDERLE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

LEDERLE's Recent FDA Approvals

New NDA/BLA approvals for LEDERLE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LEDERLE's Therapeutic Areas

LEDERLE's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 33%
2 drugs
Respiratory 17%
1 drugs
Cardiovascular 17%
1 drugs
Neurology 17%
1 drugs
Immunology 17%
1 drugs

LEDERLE Pipeline Snapshot

Active clinical trials for LEDERLE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling